Core Insights - nDatalyze Corp. has successfully completed the genetic swab and questionnaire collection for two of the three teams involved in the Epitome predictive analytics project, with the third team's data collection set to begin before October 31 and expected to conclude by the end of November [1] - The President of nDatalyze Corp., Jim Durward, highlighted exceptional player participation and the collaborative effort to leverage technology for improved performance [1] - The ongoing reverse takeover (RTO) process is experiencing delays due to the complexity of product SKUs and the tracking of items from purchase to sale, with the tax opinion for the controlling shareholder now received and finalization of paperwork underway [1] Company Developments - The RTO target audit is currently in progress, with the extended timeframe attributed to the large number of product SKUs [1] - The Corporation's shares will remain halted until the RTO is either completed or abandoned [1] - Anticipated private placement and presentation to the Canadian Securities Exchange (CSE) are in the works as part of the RTO process [1]

Group 1 - nDatalyze Corp. has announced that its sports analytics predictive scoring formulas, including genetic markers, are currently in testing and calibration [1] - The Epitome online questionnaire is now live and also undergoing testing, with data collection from three junior league teams expected to start in mid-October and conclude by year-end 2025 [1] - Machine learning has played a crucial role in the development of Epitome, significantly reducing costs and accelerating development time [1] Group 2 - The ongoing reverse takeover (RTO) process is in progress, with the controlling shareholder awaiting a tax opinion before finalizing the private placement amount [2] - Trading of the Corporation's shares will remain halted until the RTO is either completed or abandoned [2]